Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Onyx Pharmaceuticals has submitted the new drug application (NDA) with the US Food and Drug Administration (FDA) for carfilzomib as a treatment for the patients with relapsed and refractory multiple myeloma.
Subscribe to our email newsletter
Additionally, Onyx has requested priority review of the application, which reduces the time the FDA takes to review a new drug application.
Onyx Research and Development and Technical Operations executive vice president Ted Love said they believe the efficacy and safety data within the NDA submission provide a compelling basis for accelerated approval of carfilzomib in the relapsed and refractory treatment setting.